Liquidia Fails to Undo Court’s Block on New Blood Pressure Drug

The Federal Circuit approved a Delaware judge’s mixed ruling in patent dispute pitting Liquidia Corp. and United Therapeutics Corp. over competing treatments for potentially fatal high blood pressure in the lungs.

The court’s precedential opinion leaves in place Judge Richard G. Andrews’ finding that the rollout of a new Liquidia drug Yutrepia would infringe UTC’s US Patent No. 10,716,793, which covers a method of administering treprostinil by inhalation and expires in May 2027.

The opinion, penned by Judge Alan D. Lourie of the US Court of Appeals for the Federal Circuit, also backs up Andrews’ decision to invalidate five ...